A recent clinical trial published in JAMA has shown that oral glucose-lowering medications, including metformin and glyburide, are less effective than insulin in preventing large-for-gestational-age (LGA) infants in women with gestational diabetes. The study, conducted across 25 centers in the Netherlands, did not meet the criteria for non-inferiority between the two treatment options.
Study Overview
Gestational diabetes is typically managed with insulin when dietary changes fail to control blood sugar levels. However, in recent years, oral agents like metformin and glyburide have gained popularity due to their ease of use, lower cost, and higher patient acceptance. Despite their use, concerns remain about the potential long-term effects on the offspring, as well as their efficacy in comparison to insulin.
This randomized, open-label trial aimed to evaluate whether oral glucose-lowering agents could match insulin in preventing LGA infants, a common complication of gestational diabetes. Participants included pregnant women between 16 and 34 weeks gestation, aged 18 and older, who had not achieved glycemic control with diet alone. Exclusions included those with pre-existing diabetes or major fetal anomalies.
Methodology
The trial involved 820 participants, randomly assigned to receive either oral glucose-lowering agents or insulin. The oral group began with metformin, which could be escalated to glyburide if necessary. Insulin was introduced if control was not achieved. The primary endpoint was the incidence of LGA infants, while secondary outcomes included maternal and neonatal health measures such as hypoglycemia, cesarean delivery, and neonatal complications.
Key Findings
The trial found that 23.9% of infants in the oral medication group were born large for their gestational age, compared to 19.9% in the insulin group, a difference that failed to meet the non-inferiority threshold. In the per-protocol analysis, the gap remained unchanged at 3.4%. These findings suggest that oral agents were not as effective as insulin in preventing LGA infants, though the results were not statistically significant.
Moreover, secondary outcomes revealed higher rates of maternal hypoglycemia in the oral medication group (20.9% vs. 10.9% with insulin). While adverse effects like nausea and diarrhea were more common with oral agents, patient satisfaction was notably higher among those using metformin and glyburide. Neonatal intravenous glucose therapy was also more frequently required in the oral medication group (6.4% vs. 3.2%).
Conclusion
In conclusion, while oral glucose-lowering agents offer a less invasive option for managing gestational diabetes, they did not prove to be as effective as insulin in preventing LGA births. The study’s findings underscore the need for further research to assess the long-term safety and efficacy of these alternatives, especially in terms of balancing patient satisfaction with clinical outcomes. Although oral agents may reduce the need for insulin, their higher rates of hypoglycemia and adverse effects suggest that insulin remains the more reliable treatment for managing this condition.
Related topics:
Canadian Smartwatch Technology Could Eliminate Finger Pricks for Diabetics
Diabetes and Heart Disease: A Dual Challenge to Health
Key Updates in ADA 2025 Standards of Care: CGM Use for Type 2 Diabetes, Drug Shortages, and More
